Clinical Trial Detail

NCT ID NCT03319459
Title FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Fate Therapeutics

hepatocellular carcinoma

Her2-receptor positive breast cancer

head and neck squamous cell carcinoma

renal cell carcinoma

stomach cancer

colorectal cancer

Advanced Solid Tumor



FATE-NK100 + Trastuzumab

Cetuximab + FATE-NK100

Age Groups: senior adult

Additional content available in CKB BOOST